

It is almost redundant to say that the heavily regulated government-medical industry is designed to suck as much money out of us as possible and make us go into debt on top. It's about time then, that we make that

I have found the perfect company that can help us do just that. Most innovations have only made health care more expensive, but finally, that will save us all money, and make us HUGE gains on top of that!

ZenoSense (ZENO) has come up with the simplest, and most necessary medical innovation I have ever seen, and it could be the best long-term addition to your portfolio.


ZenoSense is developing an amazing medical device breakthrough that has been in demand for years. Resistant superbugs took their first victims - a new medical device incorporating patent-protected technology that can save thousands of innocent lives and billions of dollars each year.

And barely anybody knows about it aside from those of you reading this report right now.

When the first wave of mainstream investors figure this out, ZenoSense shares could easily **skyrocket from \$1 to over \$8** in a matter of months

This is no exaggeration, and I will tell you exactly where these numbers come from in this report. This may seem implausible, but it isn't. Early investors could see a \$3,000 investment soar to \$24,000 just in the short term. How exactly? Here's the first piece of the puzzle.

The Wall Street Journal reports...



To understand why there is such a huge upside with ZenoSense, we'll start with what may at first seem a silly-sounding device but in reality is anything but – an **electronic nose**, or E-Nose, that actually "smells" bacteria.



E-Noses are not new technology. In fact, they've been around for years. The most rudimentary of these devices was revolutionary in its day and still saves countless lives every year. What is that? The simple smoke detector.

Getting more sophisticated, doctors have discovered a technique of training dogs to sniff out lung cancer by smelling a patient's breath. The point is, smelling bacteria is far from fantasy.

NASA's E-Nose makes use of very expensive technology to alert astronauts of dangerous chemicals or bacteria, but no hospital can afford the kind of equipment on the international space station! Spending \$8,000 per device is just impossible to shoulder for most clinics.



But here's where ZenoSense (ZENO) comes in.

This tiny nearly unknown company is developing an E-Nose that could cost **as low as \$50** to manufacture.

And what is it designed to “sniff out”?

DRUG-RESISTANT SUPERBUGS!

How big will these things be?

The ZenoSense E-Nose will be nothing more than a card that hospital employees can wear around their necks, constantly alerting them to the tiniest presence of these life-threatening bacteria.

The most important part is that these E-noses are designed to detect the bacteria before any infection ensues!

This was previously considered impossible.

For decades the medical community has spent enormous amounts of money and capital trying to come up with ever more sophisticated and expensive ways to kill these superbugs, but they keep evolving to become more and more resistant. The ZenoSense approach is inordinately simpler and cheaper. If you stop the bacteria before

they infect, you can just sanitize the area and keep going.

If you think this is a “pretty good” investment opportunity, don’t get carried away yet... because its way bigger than that.



Superbugs are bacteria that are a tragic outgrowth of the need for a sterile environment with lots of antibiotics in it.

Constant sterilization and antibiotics eventually lead to bacteria evolving ways around these things, making the problem exponentially worse and more threatening as time goes on. In a very short time, these superbugs have evolved to become stronger and stronger.

This is why ZenoSense sales of a developed superbug detector device could spike to over \$1 billion in 12 months.

And it won't stop there as markets open up for this breakthrough sensory technology.

Early investors know what to look for, and that's triple digit gains.

Demand for a medical device like this is already extreme as the superbug threat grows by the day.

The grim numbers: 2 million people have battled superbugs since they began evolving in and around the very hospitals meant to treat them. 11,000 families saw a loved one die just last year from a drug resistant infection. From their perspective, a device such as the one ZenoSense is developing is priceless.

After years of trying to outrace these dastardly microbes, the conclusion is clear: **Early detection is the only long term solution.**



The deadliest superbug measured by number of infections and number of deaths per year is called MRSA (methicillin-resistant *Staphylococcus aureus*) and it **kills more people in America than AIDS**.



Terrifying? Absolutely. Reports suggest that 2 million Americans will become infected with a superbug this year, and that 11,000 will die. That's just here in the US. Globally, it is much worse.

The most effective 21st Century superbug treatment is what ZenoSense is offering:

PREVENTION BY EARLY DETECTION

Until now, the only possible way to detect MRSA was after a life-threatening infection had already taken hold. This is obviously not the best way, and that's an understatement. There have been improvements, but they have not been very encouraging.



In 2005, the FDA approved a device that can detect MRSA infections. But results take 24 hours, at which time a patient's life is already in serious danger.



In 2008, the FDA approved a "rapid blood test" for MRSA that cut it down to two hours. But patients are already infected.



In 2013, GE developed an MRSA test with results available in one hour. Good, but still not good enough.



Enter ZenoSense, which is developing a a card-sized detector that can spot





And the results - INSTANT!

Now you can begin to see why I am so excited about this stock. The potential gains, incredible. Being part of such an amazing life-saving effort, BEAUTIFUL.

ZENOSENSE'S TECHNOLOGY IS ALREADY PROVEN

The E-Nose is not some crackpot idea out of a comic book. It already works. Then why aren't other companies using it? No one but ZenoSense can, thanks to the licensed **patent pending technology**.

E-Nose technology has been in use on the International Space Station (ISS) for five years already.





Here's what the principle investigator into the E-Nose project at NASA's Jet Propulsion Laboratory had to say:

"The E-Nose is a 'first responder' that alerts crew members of possible contaminants in the air and also analyzes and quantifies targeted changes in the cabin environment,"

She's not the only one at NASA praising the E-nose. Carl Walz, a fellow Astronaut with 231 days logged in space is on record saying...

"Having experienced an air-quality issue during my Expedition 4 Mission on the space station, I wish I had the information that this E-Nose provides."

How big is the E-Nose on the ISS?

It's about the size of a shoebox. Equipped with 32 state-of-the-art polymer sensors that can identify a broad range of chemicals, it is there to save lives by warning of compounds responsible for electrical fires on board. Chemicals are differentiated by different responses from the E-Nose array.





Profits Protected by Patent

How does ZenoSense's patent-protected (patent-pending) E-Nose work by comparison?

How does ZenoSense's patent-protected (patent-pending) E-Nose work by comparison? ZenoSense's E-Nose has what is called "Adaptive Electronic Processing". This converts one discrete sensor into thousands of virtual sensors. These virtual sensors are capable of **any number of applications**.

This technology was developed specifically for a nuclear fusion research program at the privately held technology firm Sgenia. It was originally developed with the purpose of analyzing the exact position of plasma within a nuclear fusion reactor.

This plasma is not something you can just open up and look at, so a supersensitive detector was needed. Once detected, magnetic fields could be used to direct the plasma to the correct position within the reactor.

That same exact sensor technology was then adapted to recognize Volatile Organic Compounds (VOC's) and is already in commercial use for the detection of contamination in drinking water, monitoring algae formation and bad odor occasioned by algae destruction - this is critical, but not as critical as detecting the VOC's emitted by MRSA.

But future applications are just too big to quantify.
Cancer cell or healthy cell? An E-Nose can tell.




Just imagine the possibilities...

A programmable E-Nose to alert consumers of toxins, pollution, allergens, or pathogens. It could become standard fare for the average Joe, sold to everybody, just like everyone wears shoes. But of course, nobody has a patent on shoes...

People could set the E-Nose to sniff out anything they happen to be looking for. But we're getting ahead of ourselves, out into the long term. Let's get back to the short term

By far the most amazing breakthrough with ZenoSense's E-Nose is the cost: Just \$50 to manufacture



With every hospital worker wearing an ID-card-sized E-Nose around their neck or clipped to their shirt pocket beeping wherever the bacteria is detected, deadly MRSA infections could be completely wiped out, saving 11,000 lives every

year!

Hospitals are constantly being urged to curb the spread of superbugs, and for good reason. But up until now, they simply did not know how to go about it.

- Insurance companies who have to pay for those affected by MRSA are haranguing hospitals to more effectively deal with the problem.
- Medicare is moving to stop payments for hospital acquired infections for this exact reason. If you get it at a hospital, you're not covered!
- Recent research has revealed that superbugs could be responsible for over 100,000 deaths each year globally. The Center for Disease Control (CDC) estimates that proper prevention could save over \$30 billion a year in medical costs incurred by these infectious and deadly bacteria.

There are **nearly 6,000 hospitals** all around America and they could all **rush into ZenoSense's E-Nose** to end this plague once and for all. You as an investor need to get in before that rush begins.



At a manufacturing cost as low as \$50, no hospital is going to want to be the only one that still suffers from superbug infections. If one hospital buys in, the rest will have to follow or risk serious losses and maybe even lawsuits for not protecting their patients adequately.

**Think of all the staff at these 6,000 hospitals just in the US alone.
That's an unbelievable amount of sales... andtt incredible profits for early investors in ZenoSense.**



Hospitals won't start bragging about their new superbug weapon to the public. Nobody in hospital administration wants patients to even be aware that there is a problem in the first place.

It would be like advertising how many fly-zappers they post at each patient's door. Hospitals would prefer that nobody get too scared about staying in a hospital or what possible infections lie in wait there. But Maryn McKenna, author of *Superbug*:

The *Fatal Menace of MRSA*, tells us...

"... almost every large hospital in the United States had detected at least one MRSA infection, and a third of all the staph infections that occurred during hospital stays were caused by MRSA instead of common drug-sensitive staph."

There are nearly 10,700 hospitals in the United States. (This needs to be reconciled with the 6,000 number stated previously. I think one number is only registered, and the other is all inclusive? Not sure.) According to the AHA, the American Hospital Association, these 10,700 account for 1,721,736 hospital beds. Further, 71.3 million patients are admitted to hospitals each year. Now you can begin to see how explosive sales of the ZenoSense E-Nose can be just for the MRSA issue.

No one's expecting patients to walk off with the E-Nose. Much like a hospital gown, it would likely be required attire for patients, to be removed before they are released. The point is, 71.3 million patients a year is a huge number of people at risk that would need the E-Nose throughout their hospital stay.

These **71.3 million patients** are just here in the U.S.

In Europe, the U.K. and Japan there much, much more.



Taking those markets into account...

The number of hospitals increases by a factor of 7

The number of hospital beds goes to over 4.8 million

The number of physicians triples to 2.2 million

But this is also a crucial point to consider:

The CDC reports there aren't any new antibiotics in the immediate works that will kill all of these superbugs.

DETECTION BEFORE INFECTION IS THE BEST AND ONLY MEDICINE!

The simple truth is, you can never get rid of MRSA

- until you first know where it is.

But here comes the most shocking thing of all:

Superbugs love disinfectants!

Talk about natural selection at work. Live in an environment flooded with disinfectants long enough, and nature will figure it a way to adapt. Doctors recently found drug-resistant bacteria strains thriving in low levels of disinfectant, leading to th conclusion:



"Residue from disinfectants left on hospital surfaces might promote the growth of antibiotic-resistant bacteria."

Even when a room is completely sterilized, it can and will become infected again once any person enters that area. This is confirmed by a report compiled by researchers at Wake Forest University. It was published in the Spring 2001 issue of Emerging Infectious Diseases journal.

The relevant line is as follows:

"... these agents are transmissible by air, which means the transmission from health-care workers can occur in spite of standard infection control measures such as hand washing.

Thus, airborne transmission increases the likelihood that an outbreak can occur."

Superbugs don't care how old or young you are, how weak or strong.



MRSA has infected people from Lasik eye surgery patients to professional football players in Tampa Bay from their locker rooms. It was even found in several water treatment plants in the US. Freaky is the word here.

Imagine getting a deadly drug-resistant infection just by drinking the local tap water. Though this is undocumented as of yet, the biggest global fear is that these superbugs, which have evolved in hospitals, will ultimate spread beyond the hospital walls.

On that front, a research team from the University of Maryland has reported finding a practically indestructible MRSA bacteria at sewage treatment plants in the Midwest.

People with the highest risk of MRSA infection are those with suppressed, depressed, or compromised immune systems. Those with surgical wounds or IV lines for long periods of time are at particularly high risk.

The infection begins as a simple skin infection. From there it goes to the organs. Attacked with flu like symptoms of fever and chills, blood pressure then proceeds to drop to dangerously low levels. Slums are also an ideal breeding ground

for MRSA. Very high population density, inadequate plumbing and substandard hygiene are all exacerbating factors. And let's not forget prisons, where criminals are packed together in small quarters.

Could every corrections officer soon be wearing the ZenoSense E-Nose? Very possible. Could the US Government begin handing them out like food stamps?

ZenoSense's prime market could quickly move way beyond hospitals.



Airlines with recirculating air, tight spaces and passengers from who knows where may want a few detectors on board...



High school locker rooms, colleges football, professional sports of all kinds may want a cheap and easy \$50 insurance policy in the E-Nose



Nursing homes, children's care centers...the list of potentials goes on and on.

First things first though...

ZenoSense's immediate plans are to get to the hospital market. This is where the biggest risk of superbug infection is, and this is ground zero to opening up the rest of the potential markets.

The MRSA pandemic is already a \$4.2 billion crisis and hospitals must do all they can to put this superbug out of business -
by detecting it before it infects.

The most reliable and accurate numbers as to the size of the American hospital market are what the American Hospital Association (AHA) puts out. This gives you a very good idea of just how large it is. The AHA reports:

**5,724 registered hospitals They will all need the E-Nose to detect MRSA.
+ 4,973 community hospitals will not be left behind They will need it, too.**

That's 10,697 hospitals - just in America alone

Even if ZenoSense prices the E-Nose at \$100 a unit, hospitals will not be held back from buying large amounts. Aside from hospital administration itself, hospital insurers may require a minimum quota. After all, they are the ones paying when MRSA strikes. Insurance companies could even buy E-Noses at their own discretion and require that hospitals use them.

Doctors are a given. Nurses, too, especially the ones that treat open wounds. According to the AHA, there are...

According to the AHA, there are...

**924,333 staffed beds in registered hospitals
+ 797,403 staffed beds in community hospitals**

In total, that's 1,721,736 staffed beds!

If we add in Europe, the U.K. and Japan, there are 4,860,491 hospital beds in the Western world.

Bottom line, putting all these numbers together....

This is the immediate sales potential for ZenoSense: If America's major hospitals put an E-Nose on every bed, which

is certainly logical if they want to put an end to MRSA for good,

ZenoSense sales could easily get to \$2 billion annually...

and to over \$7 billion if hospitals in Europe, the U.K. and Japan join the trend.

Also consider the patient population itself...

One can't rule out the possibility that ordinary people will buy an E-Nose in the event that they are admitted to a hospital.

36,564,886 people are admitted to registered hospitals annually.

34,843,085 people are admitted to community hospitals annually.

That's 71,407,971 hospital patients in America alone

At this point you may be starting to see why insider investors are so excited about this prospect.

ZenoSense is the **"miracle"**
investment you've always wished
would *come your way*



European Scientists Are Engineering a Sensory Miracle

Leading the Scientific Team:

J. Lama, MBA, BSc

Mr. Lama is an engineer with a Masters in Business Administration and a Bachelor of Science (Physics). His experience includes material engineering, solid state physics, electronics, renewable energy, the automotive industry and developing technological business.

M. Querol, MS

Mr. Querol is a mechanical engineer with a Masters of Science in Telecommunications Engineering. His experience includes market development of global solutions for Aeronautical, Naval and Defense sectors, market development of internalization strategy development and market development of industrial engineering solutions.

M. I. Gil, DEA, BSc

Ms. Gil has a Masters of Advanced Studies in Fluids Mechanics from Centro Politecnico Superior of University of Zaragoza in Spain, as well as a Bachelor of Telecommunication Engineering. Ms. Gil has wide experience in sensor technologies and advanced technical and software developing.

G. Roman Perez, PhD, MAS, BSc

Mr. Perez has a PhD in Physics from the Autonomous University of Madrid (UAM), with Cum Laude distinction. He also has a Masters of Advanced Studies in Condensed Matter Physics, a Masters in Biophysics and a Bachelor of Physics, all issued by UAM. His work has been published in several different publications and he has spoken at conferences in France, Italy, Spain and the USA.

In addition, Zenosense will also rely upon a team of three biologists -molecular biologists and biochemists specializing in bacterial physiology and genetics, clinical microbiology and molecular biology. All hold relevant Ph.Ds, and two hold Masters, in disciplines highly relevant to optimizing the Company's sensor for the detection of MRSA/SA.

The team's combined skillset includes deep knowledge of the clinical genetics to be addressed in order to program and refine the sensor so that it can detect SA (regular staphylococcus aureus) and ideally discriminate between MRSA, the drug-resistant strain, and SA. Additionally, members of the team are business (biotechnology) management qualified, have co-authored numerous scientific publications, taught as professors, have experience of the practical clinical setting in hospitals and have co-invented patents for others.

While the medical community the world over continues to combat MRSA post infection and the bacteria wreaks havoc on humanity, you can not only make a huge profit by putting ZenoSense (ZENO) in your portfolio, but be part of the company that may put a final end to this superbug scourge.

Get long ZENO, take your position...

...before the investment community at large catches on. This company just went public THIS YEAR, which is why nobody on Wall Street is covering it yet. When they do, shares of ZENO could surge violently.

Fortunately, you're among the first to learn of the ZenoSense E-Nose and the opportunity it affords. **Buy your shares now** so you don't miss a single move up.

You've learned about ZenoSense and the groundbreaking E-Nose, but if you want more of my picks at no cost whatsoever, just subscribe to my newsletter. You'll never miss a single opportunity that I spot.

But first, put this stock in your portfolio: ZENO

Sincerely,
David Katz



© 2014 UnderQuarterly.com

IMPORTANT NOTICE AND DISCLAIMER: This is a paid advertisement by The UnderValued Quarterly Newsletter ("UVQ"). UVQ has received \$15,000 from or on behalf of Rolling Media Solutions Inc ("RMS") in compensation for this advertisement to enhance public awareness of Zenosense Inc ("Zenosense" or the "Company"). UVQ endorser David Katz received a fee of \$1,500. UVQ also expects to receive new subscriber revenue, the amount which is unknown at this time, as a result of this advertising effort. UVQ does not perform any due diligence on the stocks and companies discussed herein. UVQ relies on generally available public information and representations made by Zenosense. UVQ does not purport to provide an analysis of any company's financial position, operations, or prospects. This advertisement is not to be construed as a recommendation by UVQ, or an offer to sell or solicitation to buy or sell any security. Never invest in any advertised company unless you can afford to lose your entire investment. Zenosense, the Company featured in this issue, appears as paid advertising, paid by RMS to enhance public awareness for Zenosense. RMS is managing an online weekly advertising budget of up to \$120,000 USD out of a total budget of \$960,000 USD in an effort to build industry and investor awareness, paid to RMS from a shareholder(s) of Zenosense. These shareholder(s) hold a large amount of shares in ZENO and intend to sell those shares. Their sales of ZENO common stock will affect the value of your shares (negatively). This should be considered a direct conflict of interest. The payment is to cover costs associated with creating and distributing this report online and RMS will retain any excess funds as profit. Although the information contained in this advertisement is believed to be reliable, UVQ makes no warranties as to the accuracy of any of the content herein and accepts no liability for how readers may choose to utilize it. The information contained herein is based exclusively on information generally available to the public and does not contain any material, non-public information. Readers should perform their own due-diligence before investing in any security including consulting with a qualified investment advisor or analyst. Readers should independently verify all statements made in this advertisement and perform extensive due-diligence on this or any other advertised company. The feature Company's financial position and all other information regarding the feature Company should be verified directly with the Company. UVQ nor any of their principals, officers, directors, partners, agents, or affiliates are not, nor do we represent ourselves to be, registered investment advisors, brokers, or dealers in securities. UVQ is not offering securities for sale. This mailing piece is not intended to be, nor should it be construed as, an offer to buy or sell, or a solicitation of an offer to buy or sell securities, or as a recommendation of the purchase of the feature Company's securities. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. Research and any due diligence was conducted by an outside researcher for this advertisement. Further, specific financial information, filings and disclosures as well as general investor information about publicly listed companies and other investor resources can be found at the Securities and Exchange Commission website at www.sec.gov and www.nasdaq.com. Any investment should be made only after consulting with a qualified investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Many states have established rules requiring the approval of a security by a state security administrator. Check with www.nasdaq.org or call your state security administrator to determine whether a particular security is licensed for sale in your state. This advertisement is not intended for readers in any jurisdiction where not permissible under local regulations and investors in those jurisdictions should disregard it. Investing in securities is highly speculative and carries a great deal of risk, which may result in investors losing all of their invested capital. Past performance does not guarantee future results. This advertisement contains forward-looking statements regarding Zenosense, its business and prospects. Such forward-looking statements and information are within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor provisions created by these laws. The advertisement may include statements regarding expected continual growth of the featured company. Forward-looking statements are based upon expectations, estimates and projections at the time the statements are made and involve risks and uncertainties that could cause actual events to differ materially from those anticipated. Forward-looking statements may be

identified through the use of words such as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should, or might occur. Any statements that express or involve predictions, expectations, beliefs, plans, projections, objectives, goals or future events or performance may be forward-looking statements. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the publisher notes that statements contained herein that look forward in time, which include other than historical information, involve risks and uncertainties that may affect the company's actual results of operations. Factors that could cause actual results to differ include, but are not limited to, the size and growth of the market for the company's products and services, regulatory approvals, the Company's ability to fund its capital requirements in the near term and the long term, pricing pressures and other risks detailed in the Company's reports filed with the Securities and Exchange Commission. UVQ is a trademark of The UVQ newsletter. All other trademarks used in this publication are the property of their respective trademark holders. UVQ is not affiliated, connected, or associated with, and are not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by UVQ to any rights in any third-party trademarks. This advertisement may provide the addresses of or contain hyperlinks to outside or third-party websites, UVQ has not reviewed any such websites and takes no responsibility for the contents thereof or any possible effects resulting from accessing any such websites. The contents of any such websites do not in any way constitute a part of this advertisement. Accessing such websites or following any link shall be at your own risk.